• 1
    Holmberg SD, Tong TC, Ward DJ, et al. Protease inhibitor drug use and adverse cardiovascular outcomes in ambulatory HIV-infected persons. Lancet. 2002;360:17471748.
  • 2
    The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:17231735.
  • 3
    Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130139.
  • 4
    Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:4862.
  • 5
    The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:22832296.
  • 6
    Ford ES, Gilles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356359.
  • 7
    Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:3652.
  • 8
    Kuvin JT, Karas RH. Clinical utility of endothelial function testing. Circulation. 2003;107:32433247.
  • 9
    Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J. 2003;145:943951.
  • 10
    Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. Circulation. 2004;110:29182923.
  • 11
    Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995;74:247253.
  • 12
    Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911920.
  • 13
    Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257262.
  • 14
    Shankar SS, Dubé MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150(5):933.
  • 15
    Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11F18.
  • 16
    Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871875.
  • 17
    Grubb JR, Dejam A, Voell J, et al. Lopinavir-ritonavir: effects on endothelial cell function in healthy Subjects. J Infect Dis. 2006;193:15161519.
  • 18
    Torriani FJ, Komarow L, Cotter B, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over twenty-four weeks: A5152s, a substudy of A5142. Program and Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 2007; Sydney, Australia. Abstract WEAB302.
  • 19
    Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42:13251332.
  • 20
    Van Wijk JPH, De Koning EJP, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47:11171123.
  • 21
    Nolan D, Watts GF, Herrmann SE, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM. 2003;96:825832.
  • 22
    Paladugu R, Fu W, Conklin BS, et al. HIV TAT protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2003;38:549555.
  • 23
    Chai H, Yang H, Ya S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteris. J Acquir Immune Defic Syndr. 2005;40:1219.
  • 24
    Chi D, Henry J, Kelly J, et al. The effects of HIV infection on endothelial function. Endothelium. 2000;7:223242.
  • 25
    Wang X, Chai H, Yao Q, et al. Molecular mechanisms of protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44:493499.
  • 26
    Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation. 2005;112:3238.
  • 27
    Walli R, Herfort O, Michel GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167F173.
  • 28
    Dubé MP, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613627.
  • 29
    Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:2025120254.
  • 30
    Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276:3751437519.
  • 31
    Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:13781388.
  • 32
    Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:10261031.
  • 33
    Wang TD, Chen WJ, Lin JW, et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362365.
  • 34
    Van Wijk JPH, De Koning EJP, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy. Ann Intern Med. 2005;143:337346.
  • 35
    Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429438.
  • 36
    Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:29782982.
  • 37
    Hürlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. Heart. 2006;92:110112.
  • 38
    Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147:E18.
  • 39
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:2938.
  • 40
    HLR Communications. Clinical view-points: an HIV/AIDS continuing education lecture series. Understanding cardiovascular disease in HIV. HLR Communications. 20-20Understanding20CD 20in20HIV.ppt. Accessed August 1, 2007.